Retinal Vasculitis Secondary to Durvalumab

Andrade, Antonio R.; Moll‐Udina, Aina; Martin, Ruth; Cilveti, Esther; Subirà, Olaia; Disfetano, Laura; García‐Arumí, José

doi:10.1159/000511386

Cited by 1 publication

(2 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Avelumab and durvalumab are PD-L1 inhibitors commonly used in bladder cancer [77]. Ocular side effects are less common with PD-L1 inhibitors, compared to PD-1 inhibitors [80,82]. In fewer than 1% of cases, avelumab and durvalumab are associated with uveitis and iritis.…”

Section: Immune Checkpoint Inhibitorsmentioning

confidence: 99%

See 1 more Smart Citation

Potential Ophthalmological Side Effects Induced by Anti-Neoplastic Regimens for the Treatment of Genitourinary Cancers: A Review

Sakellakis¹,

Spathas²,

Tsaousis³

et al. 2022

Cureus

View full text Add to dashboard Cite

The outcomes of patients with genitourinary (GU) cancers have been steadily improving in recent years. Novel therapies have entered our armamentarium, while several other regimens are currently being studied in clinical trials. This recent explosion of new agents has improved patient survival and the quality of life for patients, but has also significantly increased the frequency of several side effects. The current review will focus on the potential ocular adverse reactions of GU neoplastic treatments. The broad spectrum of manifestations of ocular toxicity underscores the uniqueness and complexity of the anatomic, physiologic, and metabolic features of the human eye. Most side effects are mild in severity and transient, but some can be severe, disabling, and irreversible. Clinicians should be aware of complications that might be vision threatening and impact the patient's quality of life. In this review, we focused on the ocular toxicity of the antineoplastic regimens that are currently used for the treatment of GU, including prostate cancer, bladder cancer, renal cell carcinoma, testicular cancer, pheochromocytoma, adrenocortical carcinoma, and penile cancer.

show abstract

Section: Immune Checkpoint Inhibitorsmentioning

confidence: 99%

“…In fewer than 1% of cases, avelumab and durvalumab are associated with uveitis and iritis. Durvalumab has also been linked to keratitis, while Andrade et al reported a case of durvalumab-induced retinal vasculitis [80,82].…”

Section: Immune Checkpoint Inhibitorsmentioning

confidence: 99%